

1. Schmidt-Wolf I, Brandhorst D, Hertenstein C, Wetter O. Results with a modified human myeloma stem cell assay. *Klin Wochenschr* 61:1101-1103 (1983)
2. Gorschlüter M, Ziske C, Glasmacher A, Schmidt-Wolf IGH. Current clinical and laboratory strategies to augment the efficiency of immunotherapy in multiple myeloma. *Clin Cancer Research* 7(8):2195-2204 (2001)
3. Märten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowski F, Glasmacher A, Sauerbruch T, Schmidt-Wolf IGH. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. *Haematologica* 86(10):1029-1037 (2001)
4. Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Bretkreutz I, Benner A, Glasmacher A, Schmidt-Wolf IGH, Martin H, Hoelzer D, Ho AD, Lokhorst H. The joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. *Ann Hematol* 82 (10): 654-659 (2003)
5. Glasmacher A, Goldschmidt H, Mezger J, Haferlach T, Schmidt-Wolf IGH, Gieseler F. Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial. *Haematologica* 89(3):371-373 (2004)
6. Schmidt-Wolf IGH, Glasmacher A, Hahn-Ast C, Jüttner A, Schnurr T, Cremer F, Moehler T, Goldschmidt H, Busert B, Schubert R, Schwanitz G. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. *Cancer Genetics Cytogenetics* 167:20-25 (2006)
7. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf IGH, Gorschlüter M. A systematic review of phase II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. *Brit J Haematol* 132(5):584-593 (2006)
8. Von Lilienfeld-Toal M, Nattermann J, Feldmann G, Sievers E, Frank S, Strehl J, Schmidt-Wolf IGH. Activated gamma delta T cells express the natural cytotoxicity receptor NKp44 and show cytotoxic activity against myeloma cells. *Clinical Exper Immunol* 144(3):528-533 (2006)
9. Gorschlüter M, Glasmacher A, Sarazin S, Hackbarth F, Hoebert E, Orlopp K, Schmidt-Wolf IGH, Mey U. CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma. A retrospective study. *Leukemia and Lymphoma*, 48(3):506-512 (2007)
10. Bretkreutz I, Lokhorst HM, Raab MS, van der Holt BV, Cremer FW, Herrmann D, Glasmacher A, Schmidt-Wolf IGH, Blau IW, Martin H, Salwender H, Hänel A, Sonneveld P, Goldschmidt H. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide on peripheral blood stem cell collection yield. *Leukemia* 1-6, 2007 Mar 22
11. H.M. Lokhorst, I. Schmidt-Wolf, P. Sonneveld, B. van der Holt, H. Martin, R. Barge, U. Bertsch, J. Schlenzka, G. Bos, A. Croockewit, S. Zweegman, I. Bretkreutz, P. Joosten, C. Scheid, M. van Marwijk-Kooy, H. Salwender, M.H. van Oers, M. Schaafsma, R. Naumann, H. Sinnige, W. Blau, G. Verhoef, O. de Weerd, P. Wijermans, S. Wittebol, U. Duehrsen, E. Vellenga, H. Goldschmidt; for Dutch-Belgian HOVON and German GMMG. Thalidomide in induction treatment increases the very good partial response (VGPR) rate before and after high-dose therapy in previously untreated multiple myeloma. *Haematologica* 93(1):124-127 (2008)
12. Schmidt M, Sievers E, Endo T, Lu D, Carson D, Schmidt-Wolf IGH. Targeting Wnt pathway in lymphoma and myeloma cells. *Brit J Haematol*. 2009 Mar;144(5):796-8.

13. Kim Y, Strehl J, Sievers E, Gorschlüter M, Brossart P, Schmidt-Wolf IGH. CD40L transfected myeloma cells transfer prolonged immunity in vivo. *In Vivo* 24:45-48 (2010)
14. Marie von Lilienfeld-Toal, Susanne Frank, Christiane Leyendecker, Sylvia Feyler, Sarah Jarmin, Ruth Morgan, Axel Glasmacher, Angela Märten, Ingo GH Schmidt-Wolf, Peter Brossart, Gordon Cook.. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. *CII* 2010 Jun;59(6):829-39
15. Kim Y¹, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D, Schmidt-Wolf IG. In vivo efficacy of griseofulvin against multiple myeloma. *Leuk Res.* 2011 Aug;35(8):1070-3. doi: 10.1016/j.leukres.2010.10.008. Epub 2010 Nov 26.
16. B. Busert, G. Schwanitz, R. Schubert, U. Gamberdinger, I.G.H Schmidt-Wolf. Characterization of the karyotype in patients with multiple myeloma by the combination of karyotype analysis, FISH and CGH. *Int J Human Genetics*, 2011. IF(2010):0,2, (2010)10(4):217-222
17. Young Kim, Guido Reifenberger, Desheng Lu, Tomoyuki Endo, Dennis A Carson, Sanna-Marie Gast, Karoline Meschenmoser, Michael Nowak, Ingo G. H. Schmidt-Wolf. Influencing the Wnt Signaling Pathway in Multiple Myeloma. *Anticancer Res*, IF(2010):1,7, 2011; Volume 31; Issue 2, Pages 725-730
18. Schwamborn, Katharina, Gorschlüter, Marcus, Glasmacher, Axel, Schmidt-Wolf, Ingo GH for the German Refractory Myeloma Study Group. Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma. *GMS*, September 27;2011
19. Auel, Britta (1), Goldschmidt, Hartmut (2), Geer, Thomas (3), Moehler Thomas M (2), Platzbecker, Uwe (4), Naumann, Ralph (4), Blau, Igor (5), Hänel, Mathias (6), Knauf, Wolfgang (7), Nüchel, Holger (8), Salwender, Hans-Jürgen (9), Scheid, Christof (10), Weisel, Katja (11), Gorschlüter, Marcus (1), Glasmacher, Axel (1), Schmidt-Wolf, Ingo GH (1), for the German Refractory Myeloma Study Group. Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma. *Ind J Hematol*, DOI 10.1007/s12288-011-0133-1; 2012, IF 0.3
20. Kai Neben, Henk M Lokhorst, Anna Jauch, Uta Bertsch, Thomas Hielscher, Bronno van der Holt, Dirk Hose, Stefan Schmitt, Laila el Jarari, Hans Salwender, Igor Wolfgang Blau, Michael Pfreundschuh, Katja Weisel, Ulrich Dührsen, Walter Lindemann, Christian Teschendorf, Hans Martin, Christof Scheid, Mathias Haenel, Hans Guenter Derigs, Ullrich Graeven, Ingo G. H. Schmidt-Wolf, Norma Peter, Mohammed Wattad, Jörg Schubert, Martin Hoffmann, Martin Goerner, Jochen Tischler, Martin Kaufmann, Helgi van de Velde, Marc S Raab, Pieter Sonneveld, Hartmut Goldschmidt. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in Multiple Myeloma patients with deletion 17p – a Subgroup Analysis of the HOVON/GMMG-HD4 Trial. *Blood*, (IF 10,6), January 26;2012 Vol 119;no 4:940-948
21. Young Kim, Sanna-Marie Gast, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G.H. Schmidt-Wolf *In vivo* efficacy of the diuretic agent ethacrynic acid against multiple myeloma. *Leukemia Research*. 36(5):598-600 (2012). IF 2,6
22. Sonneveld P, Schmidt-Wolf IGH, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel K, Wittebol S, Bos GMJ, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van de Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk Kooy M, Dührsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt H. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized

- phase 3 HOVON-65/GMMG-HD4 trial. *J Clin Oncol.* 2012 Aug 20;30(24):2946-55. IF(2010):19,0
23. Yordanova, Anna (1), Hose, D (2), Neben, K (2), Witzens-Harig, M (2), Klein, B (2), Moehler, T (2), Goldschmidt, Hartmut (2), Schmidt-Wolf, Ingo GH. Efficacy of sorafenib in patients with refractory or recurrent multiple myeloma. *Hematological Oncology, Hematol Oncol.* 2013 Mar 15. doi: 10.1002/hon.2043. [Epub ahead of print]. IF: 2,5
 24. Young Kim¹, Tomoyuki Endo^{2,3}, Desheng Lu², Ingo G.H. Schmidt-Wolf¹. The path of the Wnt: Griseofulvin and Lenalidomide in Multiple Myeloma. *Indian Journal of Research*, im Druck, IF 1,7
 25. Schmeel LC¹, Schmeel FC, Kim Y, Endo T, Lu D, Schmidt-Wolf IG. Targeting the Wnt/beta-catenin pathway in multiple myeloma. *Anticancer Res.* 2013 Nov; 33(11):4719-26
 26. Frederic C Schmeel; Leonard C Schmeel; Young Kim, Dr.; Ingo G.H. Schmidt-Wolf. Piceatannol exhibits selective toxicity to multiple myeloma cells by inhibition of the Wnt/betacatenin pathway. *Haematol Oncol.* In Druck, IF2,1
 27. Gast SM et al. Wnt pathway in lymphoma and myeloma. Review. *Drugs of the Future.* In Druck. IF 0,6
 28. H. Goldschmidt, · M.-S. Raab, · K. Neben, · K. Weisel, · I. Schmidt-Wolf. Strategien beim rezidivierten/refraktären multiplen Myelom. *Der Onkologe* 3/2014, in Druck. IF 0,1
 29. Schmidt-Wolf I. Rezidivtherapie beim Multiplen Myelom. *Journal Onkologie*, 116-120, 2/2014.